This commentary, Beyond cost-effectiveness: a reflective commentary on adapting global health technology assessment for equity considerations in South Africa and other LMICs, published in the International Journal for Equity in Health on 14 November 2025, examines the...
Health economics and vaccine financing in the eastern Mediterranean region: A needs assessment
The article “Health economics and vaccine financing in the Eastern Mediterranean Region: A needs assessment,” published in Vaccine by Elsevier, provides a comprehensive analysis of how health economics and financing are being applied in immunization programmes across...
Exploring the uptake of economic evaluation in Spanish reports positioning medicines for public reimbursement
Spain’s first pilot integrating economic evaluations into drug reimbursement decisions reveals progress, challenges, and lessons for the future. This study by Laura Vallejo-Torres, Juan Oliva-Moreno, and Félix Lobo examines how economic evaluations (EEs) were...
Why drugs fail health technology assessment: a comparative analysis of health technology assessment rejections across seven OECD countries
In their article published in Health Economics, Policy and Law by Cambridge University Press, Filippos Papadopoulos, Erica Visintin, Ilias Kyriopoulos, and Panos Kanavos explore the reasons why certain drugs fail health technology assessments (HTAs) across seven OECD...
Designing a Roadmap for Health Technology Assessment Implementation in Algeria
This 2024 article aims to characterize the status of Health Technology Assessment (HTA) in Algeria and describe the future directions for HTA implementation according to the priorities set by local stakeholders
Health Technology Assessment (HTA) guidelines
The Department of Health (DoH) in Abu Dhabi has released comprehensive Health Technology Assessment (HTA) guidelines to guide the adoption, reimbursement, and governance of emerging health technologies. These guidelines aim to ensure that costly and innovative...
Analysis the status and spatio-temporal characteristics of the synergistic development of China’s multi-level medical insurance system
The study examines the development and spatio-temporal evolution of China's multi-level medical insurance system (MMIS) from 2011 to 2020, highlighting improvements in the coupling coordination index (CCI) which rose from a moderate disorder to a well-coordinated...
The global landscape of country-level health technology assessment processes
The global landscape of Health Technology Assessment (HTA) processes is evolving as countries strive to implement evidence-based decision-making for healthcare services. This survey, covering 104 countries, offers an insightful analysis of the current state of HTA...
Healthcare systems and health economics in GCC countries: informing decision-makers from the perspective of the Gulf health economics association
The discovery of oil has enabled GCC countries to provide universal healthcare to their citizens, but rising healthcare demands pose challenges in financing these systems effectively. Experts in health economics from the Gulf Health Economics Association held a focus...
Case for a health equity framework in HTA
Improving health equity is vital for individual and societal well-being, as evidenced by significant disparities in life expectancy across England. The National Institute for Health and Care Excellence (NICE) emphasizes the importance of reducing health inequalities,...
Economic Measures for Risk Control and Cost Containment in Healthcare in Morocco
Morocco faces significant challenges in managing healthcare expenditures amid the expansion of universal health coverage. The study aimed to evaluate economic measures designed to enhance financial sustainability, equity, and efficiency in the health sector. Using...
Prices, availability, and affordability of adult medicines in 54 low-income and middle-income countries
Published in The Lancet Global Health, the study by Lachlan Oldfield, Jonathan Penm, Ardalan Mirzaei, and Rebekah Moles examines the prices, availability, and affordability of essential medicines in 54 low- and middle-income countries. Using a secondary analysis based...
How should medicines reimbursement work? The views of Spanish experts
In their 2025 study published in Health Economics, Policy and Law by Cambridge University Press, Juan Carlos Rejon-Parrilla, David Epstein, Daniel Pérez-Troncoso, and Jaime Espín explore how medicines reimbursement should be structured in Spain. While reimbursement...

New EU regulation on Health Technology Assessment takes effect
As of January 12, 2025, the EU's Health Technology Assessment Regulation (EU 2021/2282) is officially in force, marking a significant step towards greater collaboration across 27+ countries in evaluating health technologies to improve healthcare decisions.The European...
Value-based payment for high-cost treatments in Singapore
Risk-sharing agreements (RSAs) have been introduced to allocate risk between payers and pharmaceutical companies, often taking the form of outcome-based or financial-based models. This study seeks to explore the perspectives of key stakeholders within Singapore’s...
